Eun Hee Nah, Seon Cho, Suyoung Kim, Han Ik Cho
Ann Lab Med. 2017;37(1):28-33.
In this study, the authors evaluated the clinical value of a point-of-care test (POCT) for measuring the urinary albumin-creatinine ratio (ACR) in prediabetes and diabetes. The group obtained spot urine samples from 226 prediabetic and 275 diabetic individuals during regular health checkups and measured urinary ACR by using point-of-care and laboratory quantitative tests.
The study found that the positive rates of albuminuria measured by the ACR POCT were 15.5% in prediabetes and 30.5% in diabetes. In the prediabetic population, the sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of the POCT were 92.0%, 94.0%, 65.7%, 99.0% and 93.8%, respectively; the corresponding values in the diabetic population were 80.0%, 91.6%, 81.0%, 91.1%, and 88.0%, respectively. The median ACR values in the point-of-care tests for measurement ranges of <30, 30-300 and >300 mg/g were 9.4, 46.9 and 368.8 mg/g, respectively, using the laboratory method.
The authors conclude that the ACR point-of-care test demonstrated high sensitivity, specificity and negative predictive value. This suggests that the test can be used to screen for albuminuria in cases of prediabetes and diabetes.
The full publication can be accessed here.
&copia; 2022 Abate. Tutti i diritti riservati. Tutti i marchi citati sono marchi del gruppo di società Abbott o dei rispettivi proprietari.
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessmentenAccedi ora
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney diseaseenAccedi ora